US 12,448,399 B2
Cereblon-based KRAS degrading PROTACs and uses related thereto
Jesus Raul Medina, Gilbertsville, PA (US); and Hanqing Dong, Madison, CT (US)
Assigned to ARVINAS OPERATIONS, INC., New Haven, CT (US)
Filed by Arvinas Operations, Inc., New Haven, CT (US)
Filed on Jan. 26, 2024, as Appl. No. 18/424,488.
Claims priority of provisional application 63/592,814, filed on Oct. 24, 2023.
Claims priority of provisional application 63/486,528, filed on Feb. 23, 2023.
Claims priority of provisional application 63/481,672, filed on Jan. 26, 2023.
Prior Publication US 2024/0287101 A1, Aug. 29, 2024
Int. Cl. C07D 519/00 (2006.01); A61K 31/519 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01)
CPC C07D 519/00 (2013.01) [A61K 31/519 (2013.01); A61K 31/55 (2013.01); A61P 35/00 (2018.01)] 66 Claims
 
1. A compound of Formula IVB:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R1 and R2 are each independently selected from H, halo, C1-6 alkyl, and C2-6 alkynyl;
R3 is selected from H, halo, and CN;
each QL is independently CRL or N;
each RL is independently H, halo, or CN;
each p is 1, 2, 3, 4, 5, or 6; and
R12 and R13 are each independently selected from H, C1-6 alkyl, and C1-6 alkoxy.